




prevlly

we prevent
pressure ulcers

prevlly.com


Pressure ulcer is a severe health issue impacting up to 25% patients receiving long-term care, and - at the same time - heavily increasing their treatment costs.



Pressure ulcers are painful, slow to heal, and may even lead to fatal infections



The problem grows at an alarming rate due to aging population, increase in obesity and decrease in mobility due to COVID-19




Pressure ulcer can result on average in 6 to 10 additional hospital days it takes at least 21 days to cure 1st/2nd degree pressure ulcer.



An average ulcer incremental care cost accounts up to \$13,000 per patient increase in nursing time to monitor, assess, and dress wounds; higher utilization of treatment therapies

Previlly prevents pressure ulcers at the early stage, thereby improving patient lives and significantly reducing therapeutical costs for hospitals and clinics.

Our pressure ulcer preventive patch removes the underlying factors of bedsores and therefore reduces their harmful effects




Removing the causes of pressure ulcers

Our competitive advantage comes from finding the causes of pressure ulcers and preventing them; as there is a shift from hospitals and clinics to home care, Previlly can also be used by patients and their relatives at home to improve the delivery of care.




Reducing the incidence of bedsores

Our initial evaluation trials indicate that the deployment of Previlly within the clinical workflow can reduce the incidence of pressure ulcers by up to 50% (to be confirmed in clinical trials stage).



Improving patient lives and reducing care costs

Apart from reducing healthcare expenditures, Previlly supports personnel in taking care of patients, thereby optimizing treatment therapies.



It is estimated that 2-4% of the health expenditures globally are connected with wound care and they are expected to rise due to aging and decrease in mobility.

\$40
billion

2021

Wound care
expenditures

in EU and UK

\$22
billion

2030

Advanced wound care
technologies market

Globally
Source: IDTechEx (2020)

+25%

Additionally
of hidden
market


3.2
million

Patches sold
annually

in Poland



Previlly's easy-to-use and preventive pressure-ulcer patch is positioned to stay ahead of competition in the market.



Our patent-protected and certified MVP has been well accepted among future institutional clients.



Patent-protected

ISO-certified



Recognized

Creative Business Cup
Connect & Scale Up
Innovative Company Award



167 clinical entities

signed-up for tests and
implementations



We have successfully built and tested MVP of our product, and we are currently on a way to international expansion.



Market validation



Seed funding



R&D




Quality & safety



Prototyping



User acceptance




Distribution channels



Advisory board



International expansion



Series A in details

Series B



Clinical trials preparations

- Own tests (materials, electrodes, location)
- Clinical Trials documentation preparation



Clinical trials

- Prototype testing
- Iterative development of the final product
- Final redesign



Product certification

- Certification in Europe
- Registration in Europe
- Preparation for production



Production



Sales



We are focusing on the B2B2c market. We have already partnered with leading local pharmaceutical distributors and large insitutional clients.

1

Pharma and health-product distributors

B2B2C

1st partnership already established



2

Large institutional clients

B2B2

Hospitals and clinics
Long-term senior care



3

Direct-to-consumer digital channels

B2C

Patients and their relatives for future consideration



Our core team is driven by a synergy of medical, technology and business development skills and it is backed-up with senior advisory board .



Jeremi Zgierski

CEO
(Technology, Board)



Rafał Mazur, MD

CMO
(Orthopedist, Board)



Mateusz Toruń

COO & People
(Legal, Board)



Marcin Szymański

Finance & Strategy
(Board Advisor)



Łukasz Cieśla

Business & Strategy
(Board Advisor)



Anna Wrochna

Public Relations



Karol Piątek

Legal & Grants




Karolina Kucio

Biotech Msc., Chemistry Phd
(active substances)



We are raising \$3,0 m to conduct Clinical Trials of our pressure ulcer patch and to build capabilities for further advanced wound-prevention technologies.





**MVP
with IP protection
and certification**

\$0.5 million
SEED
2019 - 2021



**Clinical trials,
certification,
production and sales
readiness**

\$3.0 million
SERIES B



**1st product go-to-
market, R&D of new
products**

Break-even
SERIES B
2024 - 2025





Anti-pressure ulcer patch.

Jeremi Zgierski

jeremi.zgierski@prevlly.com

+48 796 390 284

